TrovaGene Inc (NASDAQ:TROV), a developer of cell-free molecular diagnostics, announced today the presentation of clinical results featuring the use of its Precision Cancer Monitoring℠ (PCM) platform to detect and monitor driver mutations in both pancreatic cancer and lung cancer patients at the 2015 European Cancer Congress (ECC). The conference will take place in Vienna, Austria on September 25 – 29, 2015.

“Circulating tumor DNA has emerged as an ideal diagnostic specimen to monitor tumor genomic changes and tumor dynamics. In these data sets, we show the ability to rapidly determine response to therapy for both pancreatic and lung cancer patients,” stated Antonius Schuh, Ph.D., chief executive officer of Trovagene. “The data presented at ECC demonstrate the clinical utility of our PCM platform, and the potential to improve the standard of care for cancer patients.”

Abstracts to be presented at the 2015 European Cancer Congress

  1. Abstract title:  Kinetic Monitoring of EGFR and KRAS mutations in Urinary Circulating Tumor DNA Predicts Radiographic Progression and Response in Patients with Metastatic Lung Adenocarcinoma 
    • Collaborating Institution: University of California, San Diego School of Medicine, Hatim Husain, M.D.
    • Presentation type: Poster
    • Presentation date/time: September 27, 2015 / 9:15 a.m. to 11:15 a.m. CEST
  2. Abstract title:  Dynamics of KRAS G12/13 allele burden in circulating tumor DNA predicts survival in patients with unresectable pancreatic cancer undergoing palliative chemotherapy
    • Collaborating Institution: Herlev Hospital, Copenhagen, Julia Johansen, M.D.
    • Presentation type: Poster
    • Presentation date/time: September 28, 2015 / 9:15 a.m. to 11:15 a.m. CEST

“There is a lack of reliable biomarkers when treating pancreatic cancer patients, and these data demonstrate the ability to monitor KRAS mutations in ctDNA as well as the potential to obtain accurate information on patient prognosis and response to therapy,” stated Julia Johansen, M.D., University of Copenhagen, Denmark. “Trovagene’s assay for KRAS mutant oncogenes can assist physicians in determining the aggressiveness of a patient’s disease, and provide useful information on disease progression such that therapy can be tailored accordingly. The clinical results are encouraging, and I look forward to further evaluating this assay in additional patient cohorts.” (Original Source)

Shares of TrovaGene Inc closed yesterday at $6.69. TROV has a 1-year high of $13.58 and a 1-year low of $4. The stock’s 50-day moving average is $6.21 and its 200-day moving average is $8.43.

On the ratings front, TrovaGene has been the subject of a number of recent research reports. In a report issued on September 22, Maxim Group analyst Jason Kolbert reiterated a Buy rating on TROV, with a price target of $13, which represents a potential upside of 94.3% from where the stock is currently trading. Separately, on September 15, Cantor Fitzgerald’s Bryan Brokmeier initiated coverage with a Buy rating on the stock and has a price target of $10.

According to, which ranks over 7,500 financial analysts and bloggers to gauge the performance of their past recommendations, Jason Kolbert and Bryan Brokmeier have a total average return of -9.8% and 0.0% respectively. Kolbert has a success rate of 34.4% and is ranked #3744 out of 3766 analysts, while Brokmeier has a success rate of 44.7% and is ranked #2521.

TrovaGene Inc is a development stage molecular diagnostic company. It focuses on the development and marketing of urine-based nucleic acid tests for patient/disease screening and monitoring.